Cancer patients who took drugs to cut the risk of anemia were twice as likely to develop blood clots in the lungs or legs as other patients, a decade-long study of more than 55,000 cancer patients has found.
The study adds to mounting evidence that the risks of the commonly used drugs — known as erythropoiesis-stimulating agents or ESAs — may outweigh the benefits.
ESAs stimulate bone marrow to increase the production of red blood cells. They were first approved in cancer patients in 1991 to reduce the number of blood transfusions needed during chemotherapy.
Dallas Fort Worth Injury Lawyer Blog


